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 2 
Summary 1 
Human cytomegalovirus (hCMV), a ubiquitous beta-herpesvirus, has been 2 
associated with several autoimmune diseases.  However, the direct role of 3 
hCMV in inducing autoimmune disorders remains unclear. Here we report the 4 
identification of an autoantibody that recognizes a group of peptides with a 5 
conserved motif matching the Pp150 protein of hCMV (anti-Pp150) and is 6 
shared among patients with various autoimmune diseases. Anti-Pp150 also 7 
recognizes the single pass membrane protein CIP2A and induces the death of 8 
CD56bright NK cells, a natural killer cell subset whose expansion is correlated 9 
with autoimmune disease. Consistent with this finding, the percentage of 10 
circulating CD56bright NK cells is reduced in patients with several autoimmune 11 
diseases and negatively correlates with anti-Pp150 concentration. CD56bright 12 
NK cell-death occurs via both antibody- and complement-dependent 13 
cytotoxicity. Our findings reveal that a shared hCMV-induced autoantibody is 14 
involved in the decrease of CD56bright NK cells, and may thus contribute to the 15 
onset of autoimmune disorders.16 
 3 
Introduction  1 
Natural killer (NK) cells are innate lymphocytes that have been implicated in 2 
tumor surveillance and in early host defense against viruses (Vivier et al., 3 
2008). Human NK cells are a heterogeneous population consisting of two 4 
major subsets, including CD56brightCD16dim/- and CD56dimCD16+ cells, which 5 
exhibit different phenotypic and functional characteristics (Poli A et al., 2009; 6 
Timmons and Cieslak, 2008). A reduction in the number of circulating NK cells 7 
has been observed in several autoimmune diseases (Schleinitz et al., 2010), 8 
including rheumatoid arthritis (RA) (Aramaki et al., 2009), systemic lupus 9 
erythematosus (SLE) (Hervier et al., 2011), and primary Sjögren’s syndrome 10 
(pSS) (Izumi et al., 2006). However, the mechanism of the reduction of 11 
circulating NK cells in patients with autoimmune diseases is still obscure. The 12 
CD56bright subset comprises ~10% of circulating NK cells and produces 13 
abundant cytokines, which play an important role in the cross-talk between the 14 
innate and adaptive arms of immunity (Timmons and Cieslak, 2008). The 15 
expansion of circulating CD56bright NK cells has been correlated with the 16 
suppression of autoimmune disease activity (Bielekova et al., 2006; Li et al., 17 
2005). 18 
Human cytomegalovirus (hCMV), a ubiquitous beta-herpesvirus, has been 19 
reported to be associated with several autoimmune diseases (Pak et al., 1988; 20 
Lunardi et al., 2006; Lunardi et al., 2000; Söderberg-Nauclér, 2012; Halenius 21 
and Hengel, 2014; Barzilai et al., 2007; Igoe and Scofield, 2013; Varani and 22 
Landini, 2011). However, a clear association between hCMV seroprevalence 23 
and disease has thus far been difficult to establish, because hCMV is 24 
widespread, whereas specific autoimmune diseases are relatively rare 25 
 4 
(Halenius and Hengel, 2014). Moreover, the direct relationship of hCMV in 1 
inducing autoimmune disorders remains unclear.  2 
In the present study, we identified an autoantibody that is induced by the 3 
Phosphoprotein 150 (Pp150) protein of hCMV and is shared among several 4 
autoimmune diseases. Moreover, this autoantibody could recognize the 5 
surface protein CIP2A and induce the death of CD56bright NK cells. We also 6 
found a decreased percentage of circulating CD56bright NK cells in patients with 7 
a series of autoimmune diseases, and the number of circulating CD56bright NK 8 
cells was negatively correlated with anti-Pp150 concentration. 9 
 10 
Results 11 
Identification of hCMV peptide-specific IgG (anti-Pp150) common to 12 
several autoimmune diseases 13 
The general association between hCMV and several autoimmune diseases led 14 
us to hypothesize that there might be a common unknown mechanism 15 
involved in the pathogenesis of these diseases. We first screened a random 16 
12-mer peptide library against pooled immunoglobulin Gs (IgGs) derived from 17 
three autoimmune disease groups (10 patients each with RA, SLE, or pSS). 18 
Sixty positive phage clones were identified by enzyme-linked immunosorbent 19 
assay (ELISA), and then subjected to nucleotide sequencing. Three peptides 20 
that specifically bound to all pooled IgGs were isolated from the library. 21 
Sequence analysis showed that the isolated peptides contained a common 22 
consensus motif: KSGTGPQ (Table S1).  23 
We searched for homologous sequences of this motif in a protein data bank 24 
(Swiss-Prot database). The motif aligned with amino acid residues 1012 to 25 
 5 
1018 of the basic Pp150 protein (Pp1501012–1018) of hCMV (Table S1). 1 
We next employed western blotting to test whether Pp1501012–1018 is a de facto 2 
epitope of a CMV-derived Pp150 protein. Rabbit polyclonal antibodies against 3 
the Pp1501012–1018 peptide (Rb-anti-Pp150) were prepared, and human 4 
antibodies against Pp1501012–1018 peptide (Hu-anti-Pp150) were purified from 5 
individual patient sera using immobilized Pp1501012–1018 peptide. Both 6 
Rb-anti-Pp150 and Hu-anti-Pp150 specifically recognized a protein band 7 
corresponding to the Pp150 protein (Figure 1A). The total protein of hCMV 8 
particle was prepared and detected by anti-Pp150. One specific band between 9 
130 kD and 170 kD was observed (Figure 1B). Moreover, we detected hCMV 10 
infected and uninfected CCC-HPF-1 cells using anti-Pp150. We found that the 11 
hCMV infected cells were positively stained by anti-Pp150 (Figure 1C). 12 
To identify whether this motif is recognized by the antibodies of patients with 13 
autoimmune diseases, the heptapeptide Pp1501012–1018 was screened against 14 
a panel of serum samples. We found that Pp1501012–1018 was recognized by 15 
IgG in the sera from 41 of 102 (40.2%) patients with SLE, 39 of 90 (43.3%) 16 
patients with pSS, and 54 of 127 patients (42.5%) with RA. In contrast, only 4 17 
of 46 (8.7%) patients with osteoarthritis (OA), and 6 of 101 (6.0%) healthy 18 
controls exhibited serum IgG reactivity against Pp1501012–1018 (Figure 1D).  19 
Compared with control groups (healthy donors and patients with OA), the 20 
sensitivity and specificity of the antibody to Pp1501012–1018 in the autoimmune 21 
disease group (SLE, pSS, and RA) were 41.7% and 91.8%, respectively, with 22 
an area under the receiver operating curve of 0.763 (95% confidence interval, 23 
0.722–0.805; P < 0.0001; Figure 1E). Thus, a substantial proportion of 24 
patients across a range of autoimmune diseases shared the antibody 25 
 6 
(anti-Pp150) that exhibited significant reactivity to this CMV-derived peptide 1 
motif. Based on these results, we proposed that hCMV infection can induce a 2 
pathogenic antibody that is enriched in the context of autoimmune diseases. 3 
Specific recognition of anti-Pp150 on human CD56bright NK cells  4 
To identify whether there is a corresponding human antigen recognized by 5 
anti-Pp150, peripheral white blood cells isolated from healthy donors were 6 
probed with F(ab’)2 of Rb-anti-Pp150 by flow cytometry, and only CD56bright NK 7 
cells bound to the antibody (Figure 2A, Figure S1).  8 
NK-92 is an interleukin-2-dependent NK cell line with a similar phenotype to 9 
human CD56bright NK cells, which lacks expression of FcRIII (Gong et al., 10 
1994). We further found that Rb-anti-Pp150 bound to live NK-92 cells (Figure 11 
2B), and this interaction was blocked by Pp1501012–1018 peptide (Figure 2C). 12 
Accordingly, Hu-anti-Pp150 also bound to the surface of NK-92 cells (Figure 13 
2D).  14 
Specific recognition of anti-Pp150 to the membrane protein of NK-92 cells was 15 
further verified by confocal microscopy. Rb-anti-Pp150 was incubated with live 16 
NK-92 cells (the cell viability was assessed using trypan blue staining to count 17 
living cells to more than 95%) before the cells were fixed to a glass slide with 18 
paraformaldehyde. The specific antibody against the cytoplasmic protein 19 
Erk1/2 was used as a quality indicator to monitor the false-positive results 20 
caused by cytoplasmic proteins. The results showed that Rb-anti-Pp150 bound 21 
to the plasma membrane of NK-92 cells (Figure 2E). 22 
The cancerous inhibitor of PP2A (CIP2A) as a target autoantigen 23 
The target was precipitated from the plasma membrane protein of NK-92 cells 24 
using Rb-anti-Pp150. The specific immunoprecipitated product, with an 25 
 7 
apparent molecular weight of approximately 100 kDa in sodium dodecyl 1 
sulfate-polyacrylamide gel electrophoresis, was identified to be the cancerous 2 
inhibitor of PP2A (CIP2A) by mass spectrometry (Figure S2A,B). CIP2A has 3 
been identified as a single-pass membrane protein that inhibits PP2A and 4 
stabilizes MYC in human malignancies (Junttila et al., 2007; Junttila and 5 
Westermarck , 2008).  6 
Supporting these results, the immunoprecipitated band pulled down by 7 
anti-Pp150 IgG was recognized by anti-CIP2A monoclonal antibody (Figure  8 
3A). Given that anti-Pp150 only bound to the CD56bright subset, we first 9 
detected the expression of CIP2A in the two subsets of human circulating NK 10 
cells. CIP2A was expressed in the CD56bright subset, but was not detected in 11 
the CD56dim NK cells (Figure 3B,C). The sub-cellular locations of CIP2A in 12 
NK-92 cells, CD56bright and CD56dim NK cells were detected using anti-CIP2A. 13 
We found that CIP2A was expressed on cell membrane and cytoplasm in 14 
NK-92 cells and CD56bright subset but not in CD56dim NK cells (Figure S2C). 15 
We further performed ELISA to analyze the interaction between Rb-anti-Pp150 16 
and recombinant CIP2A protein. Rb-anti-Pp150 specifically recognized CIP2A, 17 
and this interaction was inhibited by Pp1501012–1018 peptide in a 18 
concentration-dependent manner (Figure 3D). Furthermore, we found that the 19 
level of Rb-anti-Pp150 binding to the cell membrane decreased after the 20 
expression of CIP2A in NK-92 cells was knocked down with a specific small 21 
hairpin RNA (Figure 3E, Figure S2D).  22 
We further detected the interaction between Hu-anti-Pp150 and CIP2A by 23 
ELISA. Hu-anti-Pp150 purified from the patients’ sera could also specifically 24 
recognize CIP2A, whereas control IgG did not (Figure 3F). Moreover, the 25 
 8 
interaction between Hu-anti-Pp150 and CIP2A was inhibited by the 1 
Pp1501012–1018 peptide in a concentration-dependent manner (Figure 3G). The 2 
amino acid sequence of the CIP2A protein did not match that of Pp1501012–1018, 3 
suggesting that Pp1501012–1018 might be a mimotope that has a similar structure 4 
with the epitope of CIP2A. 5 
Induction of the death of human CD56bright NK cells by anti-Pp150 6 
The number of circulating NK cells has been reported to be decreased in 7 
patients with autoimmune diseases (Schleinitz et al., 2010). Therefore, we 8 
quantified the circulating NK cells (CD56dim and CD56bright) from 82 patients 9 
with autoimmune diseases, including SLE, RA, and pSS, and compared these 10 
levels with those of 30 healthy donors (Figure S3A). The percentages of both 11 
CD56dim NK cells and CD56bright NK cells in peripheral blood lymphocytes were 12 
lower in all patients than in healthy donors (Figure 4A, B). Moreover, the 13 
numbers of CD56dim and CD56bright NK cells were decreased in patients with 14 
RA, SLE, and pSS, respectively (Figure S3B,C).  15 
We further explored the correlation between Hu-anti-Pp150 and decreased 16 
numbers of NK cells. The titer of Hu-anti-Pp150 was detected in the serum 17 
from the patients with autoimmune diseases and healthy donors. Overall, 18 
46.3% (38/82) of the patients had Hu-anti-Pp150-positive serum (Figure  19 
S3D). According to the titer of Hu-anti-Pp150, these patients were divided into 20 
the serum-positive group (serum+) and serum-negative group (serum−), and 21 
there was no difference in the percentage of CD56dim NK cells between these 22 
two groups of patients (Figure 4C). However, the percentage of CD56bright NK 23 
cells in serum+ patients was significantly lower than that in the serum− patients 24 
and healthy donors (Figure 4D), and the percentage of CD56bright NK cells was 25 
 9 
negatively correlated with the titer of Hu-anti-Pp150 in the serum+ patients 1 
(Figure 4E). Moreover, there was no significant correlation between CD56dim 2 
NK cells and the titer of Hu-anti-Pp150 (Figure S3E). 3 
Given its capacity to directly bind to CD56bright NK cells, we surmised that 4 
overproduction of anti-Pp150 might lead to the reduction of CD56bright NK cells 5 
in serum+ patients. First, we verified that anti-Pp150 had no effect on the cell 6 
cycle of NK-92 cells (Figure S3F) and was unable to induce cell death even 7 
after incubation for 24 h (Figure S3G). Considering that antibodies bound to 8 
cell-surface antigens can induce cell death via both antibody-dependent 9 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) 10 
mechanisms, we next explored the ADCC and CDC effects of Hu-anti-Pp150. 11 
NK-92 cells and CD56bright NK cells were incubated with Hu-anti-Pp150 12 
individually. Peripheral blood mononuclear cells (PBMC) were isolated from 13 
healthy donors and incubated with pre-treated cells. Then, the cell death was 14 
quantified by the measurement of lactate dehydrogenase (LDH) release. We 15 
found that Hu-anti-Pp150 triggered cell death via ADCC (Figure 4F,G). 16 
Furthemore, NK-92 cells and CD56bright NK cells were incubated with 17 
Hu-anti-Pp150 followed by addition of 20% normal human serum (NHS) or 18 
heat-inactivated NHS (inNHS). Then, the cell death was quantified by the 19 
measurement of LDH release. It was found that Hu-anti-Pp150 triggered both 20 
NK-92 and CD56bright cell death via CDC (Figure 4H,I) 21 
Rabbit IgG can bind to human C1q and activate the human complement 22 
system (Rayner et al., 2013). Therefore, we further evaluated the CDC effect 23 
of Rb-anti-Pp150 on NK-92 cells and found that Rb-anti-Pp150 induced cell 24 
death in the presence of active human serum (Figure 4J,K). Moreover, the 25 
 10 
CDC effect of Rb-anti-Pp150 was blocked by the Pp1501012–1018 peptide 1 
(Figure 4L).  2 
Mouse NK cells do not express CD56 and there is no corresponding subset to 3 
human CD56bright NK cells in mouse. In order to further elucidate the 4 
pathogenic role of anti-Pp150, we intraperitoneally injected CFSE-labeled 5 
NK-92 cells into CB-17 SCID mice together with anit-Pp150. The peritoneal 6 
cells were collected at 30 and 60 min after cell transfer. Then, the percentage 7 
of CFSE-labeled NK-92 cell was analyzed by using flow cytometry. It was 8 
found that treatment of anti-Pp150 induced the significant decrease in 9 
percentage of NK-92 cells compared with control IgG (Figure 4M).  10 
Discussion 11 
hCMV is a ubiquitous beta-herpesvirus with seroprevalence in the human 12 
population ranging between 30% and 90% in developed countries, and the 13 
prevalence increases with age (Crough and Khanna, 2009). More than 85% of 14 
the serum specimens used in this study was found to be hCMV IgG-positive 15 
(Table S2). However, no significant difference was observed in the positive 16 
rate between patients with autoimmune diseases and healthy controls. 17 
Although hCMV has been associated with several kinds of autoimmune 18 
diseases (Pak et al., 1988; Lunardi et al., 2006; Lunardi et al., 2000; 19 
Söderberg-Nauclér, 2012; Halenius and Hengel, 2014; Barzilai et al., 2007; 20 
Igoe and Scofield, 2013; Varani and Landini, 2011), it is not currently evident if 21 
and how hCMV plays a causative role in the pathogenesis and onset of 22 
autoimmunity; this is mainly due to the lack of evidence for specifically higher 23 
hCMV IgG levels in patients with autoimmune diseases. Here, an anti-Pp150 24 
autoantibody was detected in 4.0% of healthy controls and in 41.7% of patients 25 
 11 
with autoimmune diseases. These data suggested that anti-Pp150 is 1 
associated with a higher prevalence of HCMV IgG antibodies in patients with 2 
autoimmune diseases. According to our results, we propose that hCMV 3 
infection can induce a shared autoantibody that is enriched in the context of 4 
common autoimmune diseases.  5 
Human NK cells play a crucial role in hCMV infections, and thus hCMV has 6 
developed several strategies to resist against NK cell-induced death. To date, 7 
several hCMV proteins have been identified as being capable of suppressing 8 
NK cell recognition, such as UL16 (Spreu et al., 2006; Welte et al., 2003), 9 
UL18 (Cosman et al., 1997), UL40 (Tomasec et al., 2000), UL83 (Arnon et al., 10 
2005), and UL142 (Wills et al., 2005). Pp150 is a major tegument 150-kDa 11 
phosphoprotein of hCMV, which binds cyclin A2 and blocks the onset of viral 12 
lytic gene expression (Bogdanow et al., 2013). Here, we identified that 13 
anti-Pp150 induces the death of CD56bright NK cells. Whether anti-Pp150 is 14 
involved in hCMV immune evasion needs to be addressed in the future. 15 
CD56bright NK cells play a unique innate immunoregulatory role, by secreting 16 
several cytokines such as interferon gamma, tumor necrosis factor-alpha, 17 
granulocyte macrophage–colony-stimulating factor, interleukin (IL)-10, and 18 
IL-13 (Cooper et al., 2001). The expansion of CD56bright NK cells in patients 19 
with multiple sclerosis (Bielekova et al., 2006) and active uveitis (Li et al., 2005) 20 
has been observed during daclizumab (anti-IL-2R) therapy, and it has been 21 
shown to be beneficial for the remission of autoimmune diseases. Our data 22 
showed that anti-Pp150 bound to CIP2A and consequently decreased the 23 
number of CD56bright NK cells, which suggests that anti-Pp150 might be 24 
involved in the pathogenesis of autoimmune diseases. It is reported that the 25 
 12 
decrease of CD56bright NK cells is observed during Epstein-Barr virus (EBV) 1 
infection in hCMV seropositive individuals but the number of CD56dim NK cells 2 
is increased (Hendricks et al., 2014), which is not consistent with the 3 
observations in patients with autoimmune diseases. 4 
CIP2A has been identified as an oncoprotein that inhibits PP2A and stabilizes 5 
c-MYC in human malignancies (Junttila et al., 2007; Junttila and Westermarck , 6 
2008). CIP2A is located in the cytoplasm or on the cell membrane; however, 7 
most studies conducted thus far have focused on cytoplasmic CIP2A, and the 8 
function of membrane CIP2A remains unknown. In our study, we found that 9 
only CD56bright NK cells expressed membrane CIP2A in human peripheral 10 
blood mononuclear cells. Moreover, anti-Pp150 could recognize CIP2A and 11 
induce the death of CD56bright NK cells. Therefore, the function of membrane 12 
CIP2A in CD56bright NK cells needs to be addressed in the future. 13 
Antibodies are induced during infection caused by pathogens. Some 14 
antibodies against pathogen have been matched with corresponding 15 
self-antigens. In systemic sclerosis, IgG autoantibodies that bind the human 16 
cytomegalovirus late protein UL94 interacts with autoantigen NAG-2 (Lunardi 17 
et al., 2000). IgG autoantibodies present in autoimmune pancreatitis recognize 18 
both Helicobacter pylori plasminogen-binding protein and the human 19 
ubiquitin-protein ligase E3 component -recognin 2 (Frulloni et al., 2009). In this 20 
study, we found that the peptide of Pp1501012-1018 induced the antibodies 21 
against human CIP2A protein. It has been reported that autoantigen CD13 22 
becomes immunogenic during hCMV infection. Soderberg’s group has shown 23 
that human antigen CD13 may be associated with hCMV particle and then 24 
induces the production of autoantibody against CD13 (Soderberg et al.,1996; 25 
 13 
Nauclér et al.,1996). If CIP2A is incorporated with the virus particle or 1 
immunogenic during the infection, it might contribute to the production of 2 
autoantibodies.  3 
In this study, most of sera samples (99%) from patients with autoimmune 4 
disease contained IgG antibodies against hCMV. However, anti-Pp150 was 5 
detected in the sera from some patients but not in all infected individuals. We 6 
assumed that there should be some uncovered mechanisms which are 7 
responsible for the production of the autoantibody. 8 
In conclusion, we have identified hCMV-induced anti-Pp150 as an 9 
autoantibody shared in patients with autoimmune diseases, which provides a 10 
clear intrinsic connection between hCMV and autoimmune diseases. This 11 
autoantibody recognizes CIP2A on CD56bright NK cells and induces cell death 12 
via both ADCC and CDC effects. These findings provide insight into the 13 
mechanism contributing to the decreased number of circulating CD56bright cells 14 
associated with the etiology of autoimmune diseases, and help to uncover the 15 
role of hCMV infection in the pathogenesis of autoimmune diseases.  16 
Experimental Procedures 17 
Screening of peptide library  18 
A random dodecamer peptide library that expresses peptides on a phage 19 
virion was purchased from New England Biolabs. The peptide library was 20 
screened against three pooled immunoglobulin (IgGs) fractions. Each fraction 21 
was purified from the pooled sera of 10 patients with SLE, 10 patients with RA, 22 
or 10 patients with pSS respectively. To enrich for specific binding phage 23 
clones (putatively disease related), IgGs from 20 healthy donors were 24 
employed to subtract non-specific binding clones. After 3 rounds of biopanning 25 
 14 
experiments, single phage clones were assayed by Enzyme-Linked 1 
Immunosorbent Assay (ELISA). DNA was extracted from positive clones and 2 
sequenced. 3 
Preparation of anti-Pp1501012-1018 antibody 4 
Polyclonal antibodies against Pp1501012-1018 were generated in New Zealand 5 
white rabbits with standard techniques and purified on the immunoaffinity 6 
column which was prepared by conjugating the Pp1501012-1018 peptide to 7 
SulfoLink Coupling Resin (Pierce), according to the manufacturer’s instructions. 8 
Human antibodies against Pp1501012-1018 were purified from anti-Pp1501012-1018 9 
positive patient sera with the Pp1501012-1018 peptide immunoaffinity column. 10 
ADCC assay 11 
NK-92 cell lines were incubated with Hu-anti-Pp150 (10 g/ml) for 30 minutes. 12 
Human whole IgG was used as an isotype control. PBMC were isolated from 13 
healthy donors using standard density gradient centrifugation and washed 14 
three times with 1× PBS. PBMC were incubated with pre-treated NK-92 cells at 15 
an effector-to-target ratio of 50:1 for 4 hours at 37°C. Then, the cell 16 
supernatant was transferred to a 96-well plate to determine the amount of 17 
lactate dehydrogenase (LDH) released using LDH Cytotoxicity Assay Kit 18 
(Beyotime). Maxi-release was obtained by disrupting the NK-92 cells with 0.2% 19 
Triton. Min-release was obtained by spontaneous lactate dehydrogenase (LDH) 20 
release from the untreated NK-92 cells. 21 
CDC assay 22 
NK-92 cell lines were harvested and incubated with anti-Pp150 for 30 minutes 23 
followed by addition of 20% normal human serum (NHS) or heat-inactivated 24 
NHS (inNHS). Then, the cell supernatant was transferred to a 96-well plate to 25 
 15 
determine the amount of lactate dehydrogenase (LDH) released using LDH 1 
Cytotoxicity Assay Kit (Beyotime). Maxi-release was obtained by disrupting the 2 
NK-92 cells with 0.2% Triton. Min-release was obtained by spontaneous 3 
lactate dehydrogenase (LDH) release from the untreated NK-92 cells. 4 
For flow cytometry assay, the treated cells were washed twice with ice-cold 5 
PBS and stained for 15 minutes with 10 g/ml of PI. Then cell lysis was 6 
analyzed by flow cytometry.  7 
Immunoprecipitation  8 
Plasma membrane protein of NK-92 cells was extracted using Qproteome 9 
Plasma Membrane Protein Kit (Qiagen). One milligram of protein extract was 10 
precleared with 10 μg of normal rabbit IgG, and then protein A-Sepharose 11 
bead slurry (Amersham Biosciences) was added. The precleared lysate was 12 
incubated with either 20 μg of normal rabbit IgG or rabbit anti-Pp1501012-1018 13 
antibody, followed by incubation with protein A-Sepharose bead slurry. Beads 14 
were washed with phosphate buffered saline, and then boiled in Laemmli 15 
buffer. The immunoprecipitation (IP) products were analyzed by sodium 16 
dodecyl sulfate polyacrylamide gel electropheresis. 17 
Immunofluorescence confocal microscopy 18 
To determine the recognition of anti-Pp150 to the membrane protein of NK-92 19 
cells, the live NK-92 cells (the cell viability was assessed using trypan blue 20 
staining to count living cells to more than 95%) was incubated with rabbit 21 
anti-Pp150 IgG or rabbit anti-Erk1/2 IgG (Cell Signaling Technology) at a 22 
concentration of 10 μg/ml. The fluorescein isothiocyanate-conjugated goat 23 
against rabbit IgG (Rockland) was used as the detecting antibody. After 24 
washing 5 times with PBS, cells were coated on glass chamber slides. The 25 
 16 
nuclei were stained by 4′ 6-diamidino-2-phenylindole (DAPI). The labeled cells 1 
were analyzed using a Carl Zeiss LSM 510 confocal laser scanning 2 
microscope. 3 
Statistical analysis 4 
We evaluated the sensitivity and specificity of the tests with the use of 5 
receiver-operating-characteristic (ROC) curve analysis, estimating the area 6 
under the curve (AUC) with 95% confidence intervals. Statistical analysis was 7 
performed using Student’s t test and Kruskal-Wallis test with GraphPad Prism 8 
software. P values < 0.05 were considered significant (*, P < 0.05; **, P < 0.01; 9 
NS, not significant). All data are presented as means ± SD. 10 
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Figure Legends 1 
Figure 1. An antibody against the Pp1501012-1018 peptide was detected 2 
in sera from patients with autoimmune diseases. (A) Western blotting 3 
assay showing the binding of anti-Pp1501012-1018 IgG to the Pp150 protein 4 
of cytomegalovirus (CMV). The protein (1 g) was probed with rabbit 5 
anti-Pp1501012-1018 IgG (Lane 1), normal rabbit IgG (Lane 2), 6 
anti-Pp1501012-1018 IgG affinity-purified from patients with SLE, pSS, and 7 
RA, respectively (Lanes 3–5), total IgG from one anti-Pp1501012-1018 8 
IgG-negative patient with SLE (Lane 6), and total IgG from one healthy subject 9 
(Lane 7). (B) The total protein of hCMV was extracted and silver stained. 10 
Pp150 protein in the total protein was determined using anti-Pp150 by western 11 
blotting. (C) hCMV infected and uninfected CCC-HPF-1 cells were fixed and 12 
stained using anti-Pp150. The staining pattern was measured by confocal 13 
microscopy. Data represents one of three independent experiments. (D) 14 
ELISA of anti-Pp1501012-1018 IgG. Each circle represents a measurement for 15 
one patient and the dashed horizontal line indicates the cut-off value. The level 16 
of anti-Pp150 higher than cut-off value was considered to be positive. 17 
Representative results from one of three experiments are shown. (E) The 18 
receiver-operating-characteristic (ROC) curve indicating the antibody level 19 
against the Pp1501012-1018 peptide in patients with three different 20 
autoimmune diseases, including SLE(104), pSS(90), and RA(127), as 21 
compared with the level in healthy controls (101) and OA patients (46). AUC, 22 
area under the curve; CI, confidence interval. SLE, systemic lupus 23 
erythematosus; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; 24 
 23 
OA, osteoarthritis; HC, healthy control. See also Table S1. 1 
Figure 2. Anti-Pp150 specifically binds to CD56bright natural killer (NK) 2 
cells. (A) Human peripheral blood white blood cells were isolated and the 3 
specific binding of F(ab’)2 of Rb-anti-Pp150 to lymphocytes was measured by 4 
flow cytometry. FITC-conjugated anti-CD3 antibodies and APC-conjugated 5 
anti-CD56 antibodies were used to separate populations of lymphocytes. (B) 6 
Binding of Rb-anti-Pp150 to NK-92 cells was measured by flow cytometry. Live 7 
NK-92 cells (7-AAD-negative) were stained with Rb-anti-Pp150 at 10 μg/ml, 8 
then by FITC-conjugated donkey against rabbit IgG. Flow cytometry analyses 9 
on FACSCalibur (Becton Dickinson) were processed by means of CellQuest 10 
software. (C) The specific binding of Rb-anti-Pp150 on NK-92 cells was 11 
blocked by the Pp1501012–1018 peptide. Live NK-92 cells (7-AAD-negative) were 12 
probed by Rb-anti-Pp150 at 2 μg/ml, with or without Pp1501012–1018 peptide, 13 
then by FITC-conjugated donkey against rabbit IgG. Flow cytometry analyses 14 
on FACSCalibur (Becton Dickinson) were processed by means of CellQuest 15 
software. Data are representative of three independent experiments and 16 
shown as the mean ± SD. (D) Hu-anti-Pp150 specifically bound to NK-92 cells. 17 
Live NK-92 cells (7-AAD-negative) were stained with Hu-anti-Pp150 at 10 18 
μg/ml, then by FITC-conjugated mouse against human IgG. Flow cytometry 19 
analyses on FACSCalibur (Becton Dickinson) were processed by means of 20 
CellQuest software. (E) Confocal microscopy showed that Rb-anti-Pp150 21 
recognizes the membrane antigen on NK-92 cells. See also Figure S1. 22 
Figure 3. CIP2A is the autoantigen recognized by anti-Pp150.  23 
(A) The immunoprecipitation (IP) products of anti-Pp150 were detected by 24 
western blotting using the antibody of CIP2A. Data represents one of three 25 
 24 
independent experiments. (B) The total mRNA was extracted in two subsets of 1 
circulating natural killer (NK) cells, and the mRNA level of CIP2A was detected 2 
by RT-PCR. Data represents one of three independent experiments.  (C) The 3 
total proteins of NK-92 cells, CD56bright NK cells and CD56dim NK cells were 4 
extracted. And expression of CIP2A was detected using anti-CIP2A(2G10) by 5 
western blotting. Data represents one of three independent experiments. (D) 6 
The interaction between CIP2A and Rb-anti-Pp150 was determined with 7 
addition of different dosage of the Pp1501012–1018 peptide by ELISA. The 8 
scrambled peptide was used as control peptide. Data are representative of 9 
three independent experiments and shown as the mean ± SD. (E) The 10 
expression of CIP2A was knocked down with small hairpin RNA for CIP2A. 11 
Binding of Rb-anti-Pp150 to NK-92 cells was measured by flow cytometry. 12 
Data are representative of three independent experiments and shown as the 13 
mean ± SD. (F) Interaction between Hu-anti-Pp150 and CIP2A was detected 14 
by ELISA. Data are representative of three independent experiments and 15 
shown as the mean ± SD. (G) Hu-anti-Pp150 specifically bound to CIP2A, 16 
which was blocked by the Pp1501012–1018 peptide in a dose dependent manner. 17 
The scrambled peptide was used as control peptide. Data are representative of 18 
three independent experiments and shown as the mean ± SD. See also 19 
Figure S2. 20 
Figure 4. Anti-Pp150 induces the decrease of circulating CD56bright 21 
natural killer (NK) cells in autoimmune diseases. Comparison of the 22 
percentage of circulating CD56bright (A) and CD56dim (B) NK cells between 23 
patients with autoimmune diseases, including SLE(27), pSS(19), RA(34), and 24 
healthy donors(30). (C) Percentage of circulating CD56dim NK cells in 25 
 25 
anti-Pp150 serum+ and serum− patients with autoimmune diseases.  (D) 1 
Percentage of circulating CD56bright NK cells in patients with autoimmune 2 
diseases and healthy donors. Each point represents a measurement for one 3 
patient. Data are shown as the mean ± SD (A-D). (E) Correlation between the 4 
percentage of circulating CD56bright NK cells and the level of anti-Pp150 in 5 
anti-Pp150 serum+ patients. (F,G) Detection of the ADCC effect of 6 
Hu-anti-Pp150 on NK-92 (F) and CD56bright (G) cells. (H,I) Detection of the 7 
CDC effect of Hu-anti-Pp150 on NK-92 (H) and CD56bright (I) cells. (J) 8 
Rb-anti-Pp150 induced the death of NK-92 cells via the CDC effect, as 9 
determined with a lactate dehydrogenase (LDH) assay. (K) Rb-anti-Pp150 10 
induced the death of NK-92 cells via the CDC effect, as determined with flow 11 
cytometry using PI staining. In the upper panel, the CDC effect of 12 
Rb-anti-Pp150 (3 g/ml) was detected in the presence of 20% human serum 13 
(HS) or heat-inactivated human serum (inHS) at different time points. The 14 
lower panel showed the CDC effect of Rb-anti-Pp150 with different 15 
concentrations in the presence of 20% HS or inHS at 3 hr after incubation. (L) 16 
The Pp1501012–1018 peptide inhibited the CDC effect of Rb-anti-Pp150. The 17 
scrambled peptide was used as control peptide. Data are representative of 18 
three independent experiments and shown as the mean ± SD. (M) 19 
CFSE-labeled NK-92 cells were intraperitoneally injected into CB-17 SCID 20 
mice together with anit-Pp150. After 30 and 60 min, the peritoneal cells were 21 
collected and the percentage of CFSE-labeled NK-92 cell was analyzed by 22 
using flow cytometry. Data are representative of three independent 23 
experiments and shown as the mean ± SD.See also Figure S3. 24 
25 
 26 
Supplemental Information 1 
Supplemental information includes Supplemental Experimental Procedures, 2 
Supplemental References, Figures S1–S3 and Table S1-S3. 3 
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Figure S2. CIP2A was identified as the putative target autoantigen. (a) The 
immunoprecipitated products were measured by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis. The arrow indicates the specific band pulled down 
by anti-Pp150. (b) The target autoantigen was identified by mass spectrometry. The
band of interest was excised from the gel and then subjected to mass spectrometry 
analysis. According to the band length, the protein was identified as CIP2A. (c) NK-92 
cells, CD56bright and CD56dim NK cells were fixed and stained by anti-CIP2A(2G10) 
individually. (d) The expression of CIP2A in NK-92 cells was inhibited by a specific small 
hairpin RNA targeting CIP2A (sh-CIP2A). Related to Figure 3.
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Figure S3. Anti-Pp150 induces the decrease of circulating CD56bright natural killer (NK) cells in autoimmune 
diseases.(a) Lymphocytes were analysed using FITC-conjugated anti-CD3 antibodies and APC-conjugated anti-CD56 
antibodies. Natural killer (NK) cells were divided into CD56dim and CD56bright subsets based on their cell-surface density of CD56. 
(b,c) Comparison of the percentage of circulating  CD56bright (b) and CD56dim (c) natural killer (NK) cells between patients with 
autoimmune diseases (systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], and primary Sjögren’s syndrome [pSS]) 
and healthy donors. (*P < 0.05; **P < 0.01; ***P < 0.001). (d) Level of anti-Pp150 in sera from patients with autoimmune 
diseases and healthy donors control (HC) . (e) Correlation between the percentage of circulating CD56dim NK cells and the level 
of anti-Pp150 in anti-Pp150 serum+ patients. (f) NK-92 cells were incubated with Hu-anti-Pp150 for 24 h and collected. Then 
cells were permeabilize and stained with propidium iodide for cell cycle analysis by quantitation of DNA content. (g) After 
incubation with Hu-anti-Pp150 for 24 h, NK-92 cells were collected and stained with both Annexin-V-FITC and 7-AAD for 
apoptosis analysis. Related to Figure 4.
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 Table S1. Peptide sequence homologies. (Related to Figure 1). 
KSGTGPQCMV Pp150 (1012-1018)
KSGTGPQconsensus motif 
Sequence homology between the consensus motif and CMV Pp150
KSGTGPQconsensus motif
YNKSGTGPQPVSPeptide3
FKSGTGPQQYSYPeptide2
YTFHPKSGTGPQPeptide1
Common consensus motif of the three isolated phage-displayed peptides
 
 Table S2. Demographic Characteristics of the Patients and Controls. (Related to 
Experimental Procedures).  
Diagnosis No. of 
Patients 
Mean Age 
(Range) 
yr 
Gender 
Male/Female 
no. 
Systemic Lupus Erythematosus 131 38 (15-78) 10/121 
Primary Sjögren’s Syndrome 109 56 (18-79) 3/106 
Rheumatoid Arthritis 161 56 (17-83) 35/126 
Osteoarthritis 46 60 (45-79) 3/43 
Healthy donors 131 43 (22-59) 23/108 
 
 Table S3. The seroprevalence of hCMV in patients and in healthy donors. (Related to 
Discussion). 
Anti-Hcmv-IgG 
Diagnosis 
No. of 
Patients positive negtive 
Mean Age 
(Range) 
yr 
Gender 
Male/Female 
no. 
Systemic Lupus 
Erythematosus 
34 33 1 41 (18-78) 4/30 
Primary Sjögren’s 
Syndrome 
33 33 0 59 (25-77) 3/30 
Rheumatoid Arthritis 33 33 0 60 (21-83) 14/19 
Healthy donors 90 80 10 49 (23-61) 12/78 
 
